(P015) Radiation Biological Responses of MRI-Linac vs Linac in Human Head and Neck and Lung Cancer Cells

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

The 1.5-T MF generated by MRL had no effect on the viability or radioresponses of NSCLC or HNSCC cell lines in vitro. These results suggest that MRL, as a novel cancer treatment technology, has the potential not to influence the radiotherapy outcome of patients. Considering the complicated in vivo microenvironment, further in vivo study is warranted.

Li Wang, Marco van Vulpen, Zhifei Wen, Stan Hoogcarspel, David P. Molkentine, Jan Kok, Steven Hsesheng Lin, R. Broekhuizen, Kie-kian Ang, A.N. Bovenschen, Bas Raaymakers, Steven Jay Frank; UT MD Anderson Cancer Center; University of Utrecht Medical Center

OBJECTIVE: The MRI-Linac (MRL) is a novel radiotherapy technology designed to enable high cure rates with low toxicity and treatment response monitoring. However, the biological influence on radioresponses of human solid tumors within the 1.5-T magnetic field (MF) generated by MRL is unknown. Our hypothesis is that the 1.5-T MF has no influence on cell viability or radiation effects.

METHODS: Two non–small-cell lung carcinoma (NSCLC) lines (H460 and H1299) and two head and neck squamous cell carcinoma (HNSCC) lines (HN-5 and UMSCC-47) were used. The influences of a 1.5-T MF on in vitro cell viability and on cellular radioresponses were determined by cell plate efficiency (PE) and by clonogenic cell survival assay (CSA) after exposing the cells to graded single doses or fractionated 6 MV radiation using Linac (100 MU/min) or MRL (134 MU/min), respectively. The experiments were performed with cell flasks placed inside a 37°C water bath with an optimized radiation dose distribution. The radiation output of Linac and the MRL was measured with a corrected chamber. The physical dose received by the cells was verified using radiation detectors. The results were analyzed by t-test.

RESULTS: Our results supported a very strong trend that MF, as a single factor, had no influence on cell viability. No significant PE change occurred after single exposure or multiple exposures to MF compared with the Linac environment for the four cell lines (12 of 16 experiments; all P > .05) except for one experiment with the H460 cells (borderline; P = .044) andthree experiments withUMSCC-47 cells. Similarly, single exposure or multiple exposures to MF had no influence on cell radioresponse (all P > .05). When the cells were exposed to MRL or Linac treatment for up to four times, no significant changes were observed for the D0s for with MF vs without MF (all P > .05).

CONCLUSIONS: The 1.5-T MF generated by MRL had no effect on the viability or radioresponses of NSCLC or HNSCC cell lines in vitro. These results suggest that MRL, as a novel cancer treatment technology, has the potential not to influence the radiotherapy outcome of patients. Considering the complicated in vivo microenvironment, further in vivo study is warranted.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Related Content